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Purpose: Interventions made by pharmacists to resolve issues when filling a prescription 
ensure the quality, safety, and efficacy of medication therapy for patients. The purpose of this 
study was to provide a current estimate of the number and types of interventions performed 
by community pharmacists during processing of prescriptions. This baseline data will provide 
insight into the factors influencing current practice and areas where pharmacists can redefine 
and expand their role.
Patients and methods: A cross-sectional study of community pharmacist interventions was 
completed. Participants included third-year pharmacy students and their pharmacist preceptor 
as a data collection team. The team identified all interventions on prescriptions during the hours 
worked together over a 7-day consecutive period. Full ethics approval was obtained.
Results: Nine student–pharmacist pairs submitted data from nine pharmacies in rural (n = 3) 
and urban (n = 6) centers. A total of 125 interventions were documented for 106 patients, with 
a mean intervention rate of 2.8%. The patients were 48% male, were mostly $18 years of age 
(94%), and 86% had either public or private insurance. Over three-quarters of the interventions 
(77%) were on new prescriptions. The top four types of problems requiring intervention were 
related to prescription insurance coverage (18%), drug product not available (16%), dosage too 
low (16%), and missing prescription information (15%). The prescriber was contacted for 69% 
of the interventions. Seventy-two percent of prescriptions were changed and by the end of the 
data collection period, 89% of the problems were resolved.
Conclusion: Community pharmacists are impacting the care of patients by identifying and 
resolving problems with prescriptions. Many of the issues identified in this study were related 
to correcting administrative or technical issues, potentially limiting the time pharmacists can 
spend on patient-focused activities.
Keywords: pharmaceutical care, pharmacy, medications, Canada, prescriptions, drug-related 
problems
Introduction
With the increasing number of new, more complex, and costly medications, pharmacists 
are the health care professionals with the skills and training to ensure the effective 
and safe use of medications.1 Pharmacists are interested in taking on more significant 
roles to ensure their knowledge and skills are optimally utilized to improve patient 
outcomes and ensure judicious use of medications.1–3 The landscape of community 
pharmacy is changing across Canada, with each province implementing various 
mechanisms to enable changes in scope of practice, such as pharmacist prescribing, 
medication management, regulation of pharmacy technicians, and electronic drug 
information systems.1,4–6 Delivery and regulation of pharmacy practice falls under 
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provincial jurisdiction and provinces currently vary in the 
stage of their regulatory changes. Within Newfoundland and 
Labrador (NL) progress has been made to implement some 
of the above policy changes.7,8
The scope of the pharmacist’s responsibility starts with 
the patients presentation of the initial prescription to the 
community pharmacist and extends to any future point dur-
ing the medication therapy.9 At any step in the prescription-
filling process, the pharmacist may identify problems such 
as incomplete information, incompatibility with the patient’s 
current medications, or the occurrence of an adverse effect. 
Interventions made by pharmacists to resolve these issues 
ensure the quality, safety, and efficacy of the medications 
received. This function is often not recognized by patients 
or funders and may be a time consuming task.
Published evidence has demonstrated that pharmacists 
intervene on a regular basis, especially during the initial 
prescription-dispensing process.10–21 The purpose of this 
study was to provide a current estimate of the number and 
types of interventions performed by community pharmacists 
in one Canadian province during processing of  prescriptions. 
This baseline data will provide insight into the factors influ-
encing current practice and areas where pharmacists can 
redefine and expand their role.
Materials and methods
A cross-sectional study of community pharmacist prescrip-
tion interventions was completed over a one-week period 
between May and July 2010, utilizing pharmacy students 
as data collectors. Students were chosen as data collectors 
to provide exposure to research, as well as to minimize the 
increased workload of community pharmacists that would 
otherwise result from this research. Previous research in NL 
demonstrated that community pharmacists were challenged to 
find time to participate in data collection during their regular 
workday.22 One week was chosen for data collection because 
students complete a 4-week placement and are expected to 
complete other activities during this time. For the purpose of 
this study, an intervention was defined as any action required 
by the pharmacist to resolve an identified issue related to a 
prescription from a licensed prescriber.
Participants for data collection
The interventions were documented by a data collection team 
consisting of a pharmacy student and pharmacist preceptor. 
The pharmacy students were initially invited to participate 
in the study. Students were eligible for inclusion if they 
were a third-year pharmacy student at Memorial University 
of Newfoundland (MUN) completing their summer student 
placement in NL, Canada. Students were excluded if they 
were completing their placement outside of NL, due to the 
interprovincial differences in pharmacy legislation. Addition-
ally, if the students or preceptors did not consent to participate 
in the study, or the student had less than one week remaining 
in their placement, they were excluded.
The pharmacy students were responsible for completing 
the data-collection forms. Third-year pharmacy students were 
chosen due to their prior exposure in community pharmacy 
and their demonstration in coursework that they can accu-
rately understand, identify, and document interventions in 
a pharmacy setting. During the data-collection time period 
they were also required to complete at least 4 weeks in a 
community pharmacy. The pharmacists were all preceptors 
for the MUN School of Pharmacy. All preceptors undergo 
preceptor training to ensure consistency with the expectations 
of the student’s activities, including identifying and solving 
drug-related problems.
Once the students and their assigned preceptor each 
signed a consent form, the students were provided with 
a study package containing all required study materials 
and forms. The student–pharmacist pair then began data 
collection.
Data collection
The student-pharmacist pair was requested to identify all 
problems with prescriptions that required interventions, for 
all consecutive patients, during the hours worked together 
over a 7-consecutive-day period. Part of the pharmacist’s 
daily responsibility is to identify problems when filling 
 prescriptions. Students were not expected to identify addi-
tional problems, but to capture and document interventions 
that occurred in daily practice. As part of this process, the 
students recorded problems that required an  intervention. 
Information recorded included patient demographics, 
a detailed description of the problem, actions taken to resolve 
the problem, the outcome of the intervention, and the time 
estimate for the problem resolution. A question was included 
that asked the team if additional patient information would 
have helped resolve the problem, and if answered yes, to 
explain how. When the data collection form was completed, 
the pharmacist was not expected to sign each form. How-
ever, it was the responsibility of the preceptor to oversee the 
work of the student and ensure that all students’ work was 
accurately completed.
The student–pharmacist pair was not expected to catego-
rize the drug-related problem when recording the  intervention. 
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All documented interventions were coded (for the  problem, 
action, and outcome sections) independently by two 
 researchers, with a third researcher acting as tiebreaker 
when required. Coding for the type of problem was based on 
standard categories of drug-related problems, with additional 
categories added as required.23 Coding for the action and 
outcomes logically complimented the type of problem and 
was consistent with how the literature reported the interven-
tion coding process.15,17,18
The participating student-pharmacist pairs were also 
requested to record information about the pharmacy. They 
recorded the size of the town or city where the pharmacy 
was located, the type of pharmacy (eg, independent, banner, 
franchise, etc), hours during which the interventions were 
documented, and the number of prescriptions filled during 
the hours worked.
Outcomes
The outcome of interest for the pharmacy-level data included 
the percentage of prescriptions requiring intervention, cal-
culated as the intervention rate. For the intervention-level 
data, the outcomes included a description of the number and 
type of interventions, the primary action taken to resolve the 
problem, the outcome of the pharmacist’s intervention, and 
the average time required for resolution.
Analysis
Data were entered into and analyzed using Statistical Program 
for the Social Sciences (SPSS version 17; IBM, Armonk, 
NY). The characteristics of the sample were described with 
frequencies, means, and standard deviations. The interven-
tion rate was calculated for each pharmacy as the number of 
interventions per pharmacy divided by the total number of 
prescriptions filled during the hours of data collection.
Ethics approval
The Interdisciplinary Committee on Ethics in Human 
Research (ICEHR) at Memorial University of Newfoundland, 
Canada approved the research protocol.
Results
Participants
Of the 40 third-year pharmacy students enrolled in the pro-
gram, twelve were ineligible as they were completing their 
placements outside NL, 15 had already finished their work 
in a pharmacy prior to commencement of the study, and 
four expressed interest but subsequently declined. Of the 
604 licensed pharmacists in the province 28 were eligible to 
participate as they were preceptors for third year students, 
nine agreed to  participate in the study. A total of nine student–
pharmacist pairs  consented to participate in the study and 
provided data.
Data on interventions were provided from a variety of 
pharmacies with representation from rural and urban centers 
as well as different types of pharmacies (Table 1). The nine 
pharmacies involved in the data collection represented 4.6% 
of all pharmacies in NL (9/195).
Interventions
A total of 125 interventions were identified for 106 patients, 
with some patients requiring multiple interventions. The 
mean age of the patients was 54.6 years; 94.3% were 
18 years of age or older (Table 2). The majority (85.8%) 
of the patients had at least one type of medication insur-
ance while 15 (14.2%) did not have any insurance. Drugs 
involved in the interventions were categorized according 
to the American Hospital Formulary Service groupings.24 
The top five categories of medications where interventions 
occurred included central nervous system agents (26.4%), 
anti-infective agents (18.4%), cardiovascular drugs (12.8%), 
hormones (8.8%), and skin and mucous membrane agents 
(7.2%) (Table 3).
The total number of prescriptions filled during the hours 
worked over the study period was 5320. The mean inter-
vention rate was 2.8%, with a range of 1.4% to 8.7%. Most 
(76.8%) of the interventions were for new prescriptions. Of 
the 125 interventions, 120 (96%) were for prescription prod-
ucts, and the remaining five (4%) were for over-the-counter 
products filled as a prescription.
The types of drug-related problems identified are noted 
in Table 4. The top four types of problems identified were 
issues related to prescription insurance coverage (n = 22, 
17.6%), drug product not available (n = 20, 16%), dosage too 
low (n = 20, 16%), and missing information (n = 19, 15.2%). 
Table 1 Pharmacy characteristics (self-reported, n = 9)
Characteristic Result







Type of pharmacy, n (%)
 Banner pharmacy 
 Chain pharmacy 
 Franchise pharmacy 
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Table 3 Categories of medications for interventions (n = 125)
Top medication categories for interventions, n (%) Result




Skin and mucous membrane 
gastrointestinal 














Table 4 Types of drug-related problems requiring intervention 
(n = 125)
Drug-related problem n (%)
Noncompliance (drug product not available) 20 (16.0)
Dosage too low (incorrect dose or frequency written) 20 (16.0)
Dosage too high (incorrect dose written, drug interaction,  
or incorrect administration)
13 (10.4)
Needs additional drug therapy 4 (3.2)
Adverse drug reaction potential due to drug interaction 3 (2.4)
Adverse drug reaction potential due to allergy 3 (2.4)
Unnecessary drug therapy due to duplicate therapy or no  
indication
3 (2.4)
Noncompliance due to unable to administer or directions  
not understood
3 (2.4)
Adverse drug reaction potential due to unsafe drug for patient 2 (1.6)
Needs different drug product as dosage form inappropriate 1 (0.8)
Other
 Prescription insurance related problems 









Table 5  Primary  action  taken  to  resolve  identified  problems  
(n = 125)
Action taken n (%)
Call/contact the physician 86 (68.8)
Not resolved by end of data collection period 14 (11.2)
Talk to the patient 13 (10.4)
Special authorization or other insurance forms completed/ 
called or insurance issue clarified
11 (8.8)
Consult references 1 (0.8)
Table 2 Patient characteristics (n = 106)
Characteristic Result
Age in years, expressed as mean ± SD (range) 54.6 ± 20.8 (2–97)
Age categories, n (%)
  ,18 years 










Type of medication insurance, n (%)
  No prescription insurance 
  Public insurance 
  Private insurance 





Abbreviation: SD, standard deviation.
These four categories made up about two-thirds (n = 81, 
64.8%) of the total types of problems identified.
The most common action taken to resolve the problems 
identified was to call or contact the physician (n = 86, 68.8%), 
followed by, talking to the patient (n = 13, 10.4%), and 
completing required forms (eg, special authorization forms 
for third-party payers) (n = 11, 8.8%) (Table 5). Fourteen 
(11.2%) of the problems identified were not resolved by the 
end of the data-collection period. For those problems resolved 
by the end of the data-collection period, the average time 
required for each intervention was 9 minutes (±5 minutes), 
with a range of 5 to 30 minutes.
For the interventions resolved by the end of the data-
collection period (n = 111), the most common outcome was 
that the prescription was dispensed as written (n = 31, 27.9%), 
followed by dispensing a different dose (n = 26, 23.4%), clari-
fication of the prescription dispensed (n = 21, 18.9%), and 
dispensing a different drug (n = 20, 18%) (Table 6).
For 21 (16.8%) of the interventions, the data-collection 
team indicated that having more patient information would 
have helped resolve the problem. It was indicated that this 
additional information would have helped solve the prob-
lem more readily (eg, diagnosis or lab test result for dosage 
assessments).
Discussion
This study demonstrated that pharmacists in a Canadian 
province are identifying and resolving problems with 
prescriptions. Nine student–pharmacist pairs documented 
125 different interventions for problems identified in the 
prescription-filling process, with a mean intervention rate of 
2.8%. Published studies have demonstrated that pharmacists 
intervene on a regular basis, especially during the initial 
prescription-dispensing process.10–21 The rate of interventions 
in our study is consistent with published rates of interven-
tions by pharmacists of 1%–6% of prescriptions.10–15,17,19–21 
This rate of intervention appears to be somewhat consistent 
over time.15,17
The top four types of problems identified in our study 
(prescription insurance issues, drug product unavailability, 
medication dosage too low for the patient, and missing 
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information on the prescription) made up almost two-thirds 
of the problems identified. Comparison of these results 
with other published literature is challenging due to varying 
 methodology and definitions of interventions. However, 
the top categories in our study were often included in 
results of other published literature, whether from older 
Canadian  studies, or more recent studies from outside 
Canada.14–17,19–21
The top two categories in our study (prescription insur-
ance issues and drug product unavailability) would indicate 
that when an intervention on a prescription was necessary, 
it was based on more technical than clinical issues. Canada 
and its provinces are moving towards formal regulation of 
pharmacy technicians with defined roles and responsibilities, 
which will redistribute the workload to allow pharmacists to 
focus more on patient care activities.4 National and provincial 
pharmacy regulatory bodies should continue this work to help 
move the profession forward. The issue of the drug products 
not being available appears to be more evident in recent 
literature, as it was not noted as a prominent issue in older 
Canadian studies.15–17 A recent Canadian survey indicated 
this is a significant issue for Canadian pharmacists, requiring 
pharmacist time to resolve, inconveniencing patients, and 
potentially adversely affecting patients’ health outcomes.25 
Some of this workload can be alleviated if pharmaceutical 
manufacturers work diligently to ensure an adequate supply 
of medications. As also noted in our study, prescription 
insurance issues were often related to filling out forms or 
following up with insurance companies. As such, insurance 
companies should work towards streamlining the process for 
third party billing.
The third most common category of problem identified was 
the “dose of the medication too low.” Some of the burden of this 
type of problem may be alleviated once pharmacists are able to 
participate in the prescription-writing process. The pharmacy 
regulatory bodies in several Canadian provinces have moved 
towards prescriptive authority for approved pharmacists in 
specific settings, and NL is examining this practice.26
Missing information on the prescription was also a 
 common problem identified in our study. An initiative that 
may aid in the resolution of this type of issue is the practice of 
“Medication Management,” defined in NL as a set of specific 
professional activities undertaken by the registered pharma-
cist to optimize safe and effective drug therapy outcomes 
for patients.7 Currently, Medication Management includes 
activities such as adapting a prescription (eg, completing 
missing information). In addition, an electronic drug informa-
tion system (DIS) has been introduced in several provinces 
across Canada.6 The DIS provides comprehensive medication 
profiles, which may help provide additional information that 
the pharmacist can use to identify problems. Both of these 
initiatives began after the data collection period for this study, 
and further study is needed to evaluate the impact of these 
practice changes on the types of interventions occurring.
Most of the interventions documented in our study 
were for new prescriptions (77%), consistent with other 
studies.11,13,15,17 The incidence of chronic diseases, such as 
diabetes and hypertension, are increasing, and medication 
adherence rates for these conditions are often suboptimal.27,28 
Interventions on refill prescriptions that may optimize adher-
ence are crucial to disease management, and initiatives that 
allow the pharmacist to spend more time on clinical versus 
technical functions should help improve this. In addition, 
monitoring chronic diseases and optimizing medication 
use should be a focus of the renewal process. Individual 
pharmacists and pharmacy regulatory bodies should work 
towards the goal of optimizing chronic disease –medication 
adherence and medication use.
Several limitations should be considered when interpret-
ing the results of the study. The sample of pharmacies was 
not random, as pharmacies participating in the study had 
already agreed to precept a student during their summer 
placement. The pharmacists were serving as preceptors, so 
their screening and intervention activities may have been 
different from community pharmacists not supervising 
 students. This study utilized pharmacy students as part of 
the data- collection team to expose students to research meth-
odology and participation, as well as to minimize additional 
pharmacist workload. Previous research in this province 
indicated that many community pharmacists do not have 
time to dedicate to collecting data, so we chose this method 
as a way to minimize the workload on the pharmacist and 
still enable this research to be carried out. This resulted in a 
Table 6 Outcome of interventions by pharmacist to resolve 
identified problem (n = 111)
Outcome n (%)
Prescription dispensed as written 31 (27.9)
Different dose dispensed 26 (23.4)
Clarified prescription dispensed 21 (18.9)
Different drug dispensed 20 (18.0)
Different frequency of drug dispensed 4 (3.6)
Drug not dispensed 3 (2.7)
Additional drug recommended and dispensed 2 (1.8)
Additional monitoring recommended 1 (0.9)
Drug discontinued 1 (0.9)
Special authorization sent 1 (0.9)
Other 1 (0.9)
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shorter data-collection period and fewer interventions than 
other published studies.10,16,20,21 Also, beyond the definition of 
an intervention and the structure of the forms, students and 
pharmacists were given no specific training in identifying 
interventions for the purpose of this study. However, students 
and pharmacists have received training, as part of their edu-
cation, to enable them to accurately identify and document 
interventions. Although the pharmacies involved were from 
a range of rural/urban settings and types of pharmacy, the 
small number of participating pharmacies makes the results 
less generalizable to a broader setting. Future research in this 
area would need to take into account the limitations noted, as 
well as the potential change in practice with increased scope 
of practice for pharmacists.
Conclusion
This study showed that pharmacists are spending time 
intervening on prescriptions to ensure patients are receiving 
safe and effective therapy. Pharmacists are spending time 
intervening on technical or administrative issues, such as 
medication insurance coverage, missing information, and 
drug shortages, which may not be an effective use of their 
time and skills. While this study gives information about 
the current work environment, further research is needed to 
assess whether changes in scope of pharmacists’ practice will 
allow more time for patient-centered care.
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